Press Releases

    Print Page  Close Window
Printer Friendly Version View printer-friendly version
<< Back
BioMed Realty Trust Promotes Matthew G. McDevitt to Executive Vice President, Real Estate
SAN DIEGO, Feb 17, 2010 /PRNewswire via COMTEX/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced the promotion of Matthew G. McDevitt to the newly created position of Executive Vice President, Real Estate, where he will oversee the company's acquisitions and leasing strategies with a focus on maximizing the value of the company's assets, while continuing to implement and manage the execution of these strategies throughout the company's markets. Most recently, Mr. McDevitt served as Executive Vice President, Acquisitions and Leasing, having joined the company in 2004.

(Logo: http://www.newscom.com/cgi-bin/prnh/20091005/BIOMEDLOGO)

"I am very pleased to announce Matt's newly expanded role of Executive Vice President, Real Estate," said Kent Griffin, BioMed's President and Chief Financial Officer. "As one of BioMed's founders, Matt has been at the center of our success in building a world-class tenant roster within every one of our seven core markets. Over the past two years alone, he has expertly managed our two regional leasing teams in the execution of more than 2.3 million square feet of new leases, lease extensions and renewals. In addition, Matt has established exceptionally strong relationships throughout the life science industry and has guided and mentored the acquisition and leasing team members as they assume greater responsibilities and leadership in executing the company's strategies."

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(R). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed owns or has interests in 69 properties, representing 112 buildings with approximately 10.5 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at http://www.biomedrealty.com/

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing, the use of debt to fund acquisitions and developments, and the ability to refinance indebtedness as it comes due; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE BioMed Realty Trust, Inc.